a scientist in the fermentation lab

Our technology portfolio to address pro-/ post-/ pre- and synbiotics

With regard to the development of probiotics, our technology portfolio offers the perfect blend of optimizing the performance of microorganisms and elucidating, exploring and exploiting molecular targets (in microbes and humans).

Outside the box:
We specialize in tailored approaches so that we can isolate and characterize new or better strains and then select microorganisms superior to others. Therefore, no two screening processes are alike.


Our in vitro tests are designed to reflect natural growth and stress conditions. This is the basis for achieving results that are transferable in vivo.

We elucidate the mode of action of microbial strains and then use this to develop a product with superior and consistent probiotic performance.

Contact our expert

Dr. Jessica Rehdorf

is our expert in the field of probiotics

View her profile

Our arsenal of technology – A modular system to choose from:


The BRAIN BioArchive (~53.000 strains) covers a wide range of habitats and substrates and includes specialized (ready-to-screen) sub-collections. We offer state-of-the-art targeted isolations and enrichment campaigns.

In-house NGS & bioinformatics

Oxford nanopore sequencing is routinely used for transcriptomic analyses and in the elucidation of the complete genome. Our in-house bioinformatics allows the evaluation and analysis of data sets (enzymes, metabolites, gene clusters) as well as the predictions of phenotypic properties. In collaboration projects, internal as well as external NGS options are available to answer questions about genome sequence variation or transcriptional patterns in the fastest and most cost-effective way.


State-of-the-art recombinant techniques (genome-wide libraries, gain/loss of function, reporter genes) help unveil the mode of action. Untargeted (laboratory evolution) and targeted (natural transformation or CRISPR) genome editing tools are applied to deliver optimized product strains.


Safety, economic producibility and stability are keystones of baseline strain characterization and minimize drop-outs during the development process. Our in vitro assays for (anti)microbial testing of strains or our cell-based assays, as well as our in-house analytics extend the phenotypic characterization and support the prioritization and selection of the most suitable strains.

tailored to fit

Precise non-GMO genome modification (using natural transformation or CRISPR) focuses on the inherent genetic makeup of strains and aims to leverage their maximal potential.


Probiotic performance indicators are based on the assessment of metabolic (e.g. enzymes, SCFA), microbial (prebiotic, cross-feeding, antimicrobial) and host-microbe (gut/ skin health receptor cell-based assays) activities.

What is beneficial for whom?

  • Non-GMO precise modification: customers looking to overcome specific issues (production, stability) of strains without risking collateral damage to performance properties
  • Evolutionary optimization: customers with precise expectations about the performance requirement of the microorganism candidates, but who do not know their corresponding capabilities
  • Expand product business
  • Science-based products to differentiate in the market
  • Increase leadership role
  • Step into new applications and market segments (cross-selling)

BRAIN Biotech – your technology provider

Do you want to learn more about your probiotic strains, elucidate the mode of action, uncover new claims, increase performance and efficiency or meet stability criteria for an application? We can support you on the way to safe, stable and producible strains and products that really stand out in the market.

Learn more about our offers regarding probiotics

Probiotic strains

Probiotics – mighty little helpers at your service

To overview

a collage of probiotic strains

Meet our microbes

Pre-characterized microbial strains

Share this page